Physician profile
Alexander Shpaner
NPI 1538334974
$7,960.52
in general payments reported to CMS, 2019-2025
20 companies · $3,456 in 2025
The $3,456 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $676 · 2021: $1,095 · 2022: $549 · 2023: $167 · 2024: $523 · 2025: $3,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,950 · Food and Beverage: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,950.00 |
| Food and Beverage | $1,195.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Medical Systems Corporation | $2,950.00 | 2025 | Evis Exera III Duodenovideoscope |
| Abbvie INC. | $1,659.94 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $881.09 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $448.99 | 2019-2025 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $338.18 | 2019-2024 | Entyvio |
| Nestle Healthcare Nutrition INC. | $321.77 | 2020-2023 | |
| Braintree Laboratories, INC. | $197.66 | 2019-2021 | |
| Pfizer INC. | $193.99 | 2019-2025 | |
| Qol Medical, LLC | $180.03 | 2019-2020 | |
| Daiichi Sankyo INC. | $163.27 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $124.91 | 2019 | |
| Ironwood Pharmaceuticals, INC | $122.93 | 2020-2023 | Linzess |
| Celltrion USA INC. | $110.59 | 2024-2025 | Vegzelma |
| Allergan, INC. | $53.19 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $49.11 | 2023 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $47.42 | 2024 | |
| Redhill Biopharma INC. | $44.36 | 2020 | |
| Medtronic, INC. | $41.88 | 2025 | Endoflip |
| Vivus LLC | $17.00 | 2019 | |
| Novo Nordisk INC | $14.21 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Shpaner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.